Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
21-valent pneumokokkenconjugaatvaccin veilig en immunogeen bij gezonde volwassenen
mei 2023 | Pneumonie, Vaccinatie